secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0000950170-23-026241
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC
---------------------------------------------------------------------------

- Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.
- Median PFS: 5.4 mo (Z), 9.3 mo (DZ), 9.9 mo (EDZ); 12-month PFS rates 25%, 41%, 44%.
- ORR: Z 30%, DZ 40%, EDZ 44%; median DoR not reached for DZ, 23.7 mo for EDZ.
- No unexpected safety signals; infusion-related reactions low (4-12%) across arms.
- Data from 150-patient randomized Phase 2 at ~18-month median follow-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/0000950170-23-026241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/rcus-20230603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer